The legal action, filed by the firm SueWallSt, centers on a period between April 16, 2025, and May 4, 2026. Following the company’s disclosure of a $31.2 million impairment charge and a $65 million reduction in annual revenue guidance, GeneDx shares plunged $33.42. The complaint invokes Section 20(a) of the Securities Exchange Act of 1934, arguing the executives served as "controlling persons" who possessed the authority to influence public disclosures.

Plaintiffs contend that Stueland and Feeley violated Sarbanes-Oxley certification requirements by attesting to the accuracy of financial filings while allegedly aware of material failures within the Fabric Genomics division. The suit claims the defendants maintained that the acquisition was on track despite evidence of underperformance. While the deadline for lead plaintiff applications is August 3, 2026, investors who do not seek this role remain eligible to participate in any eventual recovery without filing individual motions.